Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations

Provided By PR Newswire

Last update: May 6, 2025

— Company Grants Mylan a License to Market Generic CINVANTI^® and APONVIE^® Beginning in June 2032 —

CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company entered into a settlement agreement with Mylan Pharmaceuticals, Inc. ("Mylan"), a Viatris Inc. company, to resolve the ongoing patent litigations between the parties in the U.S. District Court for the District of Delaware related to CINVANTI^® (aprepitant) injectable emulsion and APONVIE^® (aprepitant) injectable emulsion. Pursuant to the terms of the settlement agreement, the Company has granted Mylan a license under the Orange Book-listed patents for CINVANTI^® and APONVIE^® (the "Heron Patents"), to market generic versions of CINVANTI^® and APONVIE^® in the United States beginning June 1, 2032, or earlier under certain customary circumstances.